Last reviewed · How we verify
NCT05015764
Reprieve Cardiovascular System for the Treatment of Subjects With Acute Decompensated Heart Failure Mechanistic Study
NA trial testing Fluid Management in Heart Failure in 31 participants. Completed in 2 May 2022.
2 May 2022
Quick facts
| Lead sponsor | Reprieve Cardiovascular, Inc |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 31 |
| Start date | 12 April 2021 |
| Primary completion | 2 May 2022 |
| Estimated completion | 2 May 2022 |
| Sites | 1 location across Georgia |
Drugs / interventions tested
- Fluid Management
- Reprieve Cardiovascular System
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Reprieve Cardiovascular, Inc — full company profile →
Who can join
18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Reprieve Cardiovascular System for the Treatment of Subjects with Acute Decompensated Heart Failure Mechanistic Study
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Edema formation in congestive heart failure and the underlying mechanisms.
Abassi Z, Khoury EE, Karram T, Aronson D. · · 2022 · cited 48× · PMID 36237903 · DOI 10.3389/fcvm.2022.933215 -
Novel Therapeutic Devices in Heart Failure.
Guzik M, Urban S, Iwanek G, Biegus J, et al · · 2022 · cited 5× · PMID 35893394 · DOI 10.3390/jcm11154303
Verify or expand the search:
- PubMed search for NCT05015764
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fluid Management
Trials testing the same drug.
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Reprieve Cardiovascular, Inc trials
Trials by the same sponsor.
- NCT06362668 — EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU) · NA · completed
- NCT06272734 — Reprieve System Pilot Study · NA · recruiting
- NCT05174312 — Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05015764 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Reprieve Cardiovascular, Inc
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05015764.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing